Rosen Law Firm warns investors of GSK and FMC class action deadlines

In New York, on March 16, 2025, the Rosen Law Firm announced important details regarding two separate securities class actions against GSK plc and FMC Corporation. Notably, purchasers of GSK’s American Depositary Receipts (ADRs) within the timeframe of February 5, 2020, to August 14, 2022, are urged to take action before the lead plaintiff deadline on April 7, 2025. A class action lawsuit has been filed with allegations that GSK misled investors about the safety and liability regarding Zantac, a drug removed from the market due to concerns over NDMA, a cancer-causing agent linked to it. The revelations surrounding these claims highlight the severe implications for GSK and its investors who might be entitled to compensation without upfront costs due to contingency fee arrangements. Simultaneously, the Rosen Law Firm is notifying investors of FMC Corporation about a class action concerning securities purchased between November 16, 2023, and February 4, 2025, with a lead plaintiff deadline set for April 14, 2025. The lawsuit against FMC claims misrepresentation regarding channel management initiatives, pricing strategy, and overall business operations, leading to inflated inventories and misleading reassurances to investors about company performance. Investors are encouraged to retain qualified legal counsel and must act before the respective deadlines to protect their interests. Both cases represent a growing trend in litigation against corporations for allegedly misleading their shareholders regarding critical operational assumptions. The attention on GSK and FMC is part of a broader concern regarding transparency from publicly traded companies in the face of significant market pressures and regulatory responsibilities. Investors are reminded of their rights and potential remedies available to them if they believe they have been misled by such representations. These lawsuits form a crucial element in investor advocacy and accountability, particularly in a financial landscape often characterized by uncertainty and upheaval. The outcomes of these cases could significantly affect not only the companies involved but also set precedents for future investor protection and corporate governance. The Rosen Law Firm has a reputation for handling securities class actions and encourages investors to join the respective classes or seek legal advice promptly. The firm has been recognized for its high number of successful settlements, particularly in the realm of securities class actions. As these cases unfold, it will be essential for affected investors to stay informed about their rights and the potential developments that could arise from these ongoing litigations.